On Monday April 26, 2021, Knowledge Ecology International submitted comments regarding the “Prospective Grant of an Exclusive Patent License: N-butyldeoxynojirimycin To Treat Smith-Lemli Opitz Syndrome (SLOS) and Diseases That Exhibit a Similar NPC-Like Cellular Phenotype” (86 FR 18545) by the… Continue Reading →
On April 27th, a letter signed by 41 Canadian experts was sent to the Prime Minister of Canada, the Minister of Innovation, Science & Industry, and the Minister of Health. The letter requests the amendment of Schedule 1 of the… Continue Reading →
On 22 April 2021 the World Trade Organization’s (WTO) TRIPS Council addressed the proposal for a waiver from certain provisions of the TRIPS Agreement for the prevention, containment and treatment of COVID-19 (IP/C/W/669) in an informal session of the TRIPS… Continue Reading →
(Update: The NIH provided a response to our comments on April 15, 2021.) Knowledge Ecology International (KEI) submitted comments on April 14, 2021 to the Federal Register notice for the National Institutes of Health’s (NIH) “Prospective Grant of Exclusive Patent… Continue Reading →
(Update: The NIH provided a response to our comments on April 15, 2021.) On Wednesday April 14, 2021, Knowledge Ecology International (KEI) filed comments with the National Institutes of Health (NIH) regarding the “Prospective Grant of an Exclusive Patent License:… Continue Reading →
On 4 December 2020, Ethiopia submitted a Zero Draft resolution to the World Health Organization (WHO) on Strengthening Local Production of Medicines and Other Health Technologies to Improve Access – WHO Resolution on Strengthening Local Production of Medicines and Other… Continue Reading →
The number of standard and material CRADAs executed by the NIH from 1985 to 2020 and the relationship to NIH reasonable pricing clause KEI Briefing Note 2021:3 James Love April 5, 2021 KEI-BN-2021-3
On March 31, 2020, KEI received a copy of the contract between Johnson & Johnson (“J&J”) and the Department of Health and Human Services (HHS) for the development of J&J’s COVID-19 vaccine.The contract, which is now valued at $1.3 billion,… Continue Reading →
Canadian Experience with Compulsory Licensing under the Canadian Access to Medicines Regime KEI Briefing Note 2021:2 31 March 2021 Arianna Schouten PDF available here: KEI-Briefing-Note-2021-2-CAMR-Canadian-Compulsory-Licensing
(Update: On April 30, 2021, the NIH sent a response to KEI’s comments.) On March 30, 2021, Knowledge Ecology International (KEI) filed comments regarding the National Institute of Health (NIH) National Institute of Allergy and Infectious Diseases (NIAID), “Prospective Grant… Continue Reading →